Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- NEW PRODUCT／Sanofi-aventis: Clexane Kit for SC Injection
May 19, 2008
- TOPICS／Mylan Accepted as JPMA Member
May 19, 2008
- Asahi Kasei Pharma: Sales Up 6.5% to \111.2 Bil.
May 19, 2008
- Nihon Chouzai Promotes Dispensing of Generics
May 19, 2008
- Bonalon Drives Teijin's Pharma Business
May 19, 2008
- OBITUARY／Dr Yutaka Mizushima: Former Chairman of LTT-Bio Pharma
May 19, 2008
- Kyowa Hakko: Sales Up 10.7% to \392 Bil.
May 19, 2008
- REGULATORY NEWS IN BRIEF
May 19, 2008
- Santen: Overseas Sales Account for 14.3% of Total Sales
May 19, 2008
- Prof. H. Endo Elected Chairman of Chuikyo
May 19, 2008
- MTPC: Remicade Continues Strong Growth
May 19, 2008
- JMA Has Not Yet Decided on Its Stance Regarding the FPMAJ's Pricing System Reform Proposal: Dr Takeshima
May 19, 2008
- Takeda: Heavy R&D Costs Cut Operating Profits
May 19, 2008
- Korosho to Consider Creating Japanese Version of FDA
May 19, 2008
- Pletaal Launched in Sweden: Otsuka
May 19, 2008
- Life Science Summit Calls For Creation of Japanese Version of FDA, NIH, OSCHR
May 19, 2008
- Bayer to Grow Twice as Fast as Market Aiming at \200 Bil. Sales: President J-L Lowinski
May 19, 2008
- Divergent Opinions on Japanese Version of FDA among LDP Members
May 19, 2008
- Daiichi Sankyo to Apply for Combination of Olmetec and Calblock
May 19, 2008
- Banyu's Isentress Roughly Recommended for Approval
May 19, 2008
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…